The field of thromboprophylaxis for acutely ill medical patients, including those hospitalized
for COVID-19, is rapidly evolving both in the inpatient setting and the immediate post …

Introduction Hospitalized COVID-19 patients, particularly those with high-risk features, are at
risk for venous and arterial thromboembolic events for approximately 30 days or more after …

2 Vascular Medicine 00 (0) most current guidelines. Both the International Society of
Thrombosis and Haemostasis (ISTH) and the European guidelines do not recommend …

Background Hospitalized COVID-19 patients are at high risk of venous thromboembolism
(VTE). Standard doses of anticoagulant prophylaxis may not be sufficiently effective for the …

Early in the pandemic, it was recognized that infection with COVID-19 was associated with
an increased incidence in both venous and arterial thrombotic events leading to poor patient …

There is a widely expressed concern about an unmet need for post hospitalization venous
thromboembolism (VTE) prophylaxis in medically ill patients, however, physicians and …

Thromboprophylaxis in hospitalized patients with COVID-19 has been associated with a
survival benefit and is strongly recommended. However, the optimal dose of …

Coronavirus disease 2019 (COVID-19) emerged as a potentially lifethreatening disease
characterized by multiorgan involvement, high rate of venous thromboembolism (VTE) …

Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with
increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in …

Background Patients hospitalized with COVID-19 often exhibit markers of a hypercoagulable
state and have an increased incidence of VTE. In response, CHEST issued rapid clinical …